✦ LIBER ✦

Use of IIb/IIIa inhibitors in patients with acute coronary syndromes who do not undergo percutaneous coronary intervention

✍ Scribed by Mardi Gomberg-Maitland; Jonathan L Halperin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

IIb/IIIa inhibitors: Effects on acute ou

✍ Mark Horrigan 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 243 KB

GPIIb–IIIa antagonists reduce thromboinf

✍ M. I. FURMAN; L. A. KRUEGER; M. D. LINDEN; M. L. FOX; S. P. BALL; M. R. BARNARD; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Planned Versus Provisional Use of Glycop

✍ Jason O. Robertson; A. Michael Lincoff; Kathy Wolski; Eric J. Topol 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Efficacy and safety of argatroban with o

✍ Ignacio Cruz-Gonzalez; Maria Sanchez-Ledesma; Suzanne J. Baron; Josephine L. Hea 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 138 KB

Assessment of use of Glycoprotein IIb/II

✍ K.J. Shah*; K.H. Parikh; M.C. Chag; U.G. Shah; A.H. Chandarana; H.A. Baxi; A.M. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Procedural Glycoprotein IIb/IIIa inhibit

✍ Michael Mok; Alexander J. Black; David Clark; Andrew E. Ajani; Stephen J. Duffy; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 59 KB